STOCK TITAN

Arbutus Biopharma Corporation - ABUS STOCK NEWS

Welcome to our dedicated page for Arbutus Biopharma Corporation news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharma Corporation stock.

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection (cHBV). Utilizing its extensive expertise in virology, Arbutus focuses on developing a portfolio of drug candidates with multiple mechanisms of action aimed at curing Hepatitis B virus (HBV) disease. The company's lead RNA interference (RNAi) therapeutic, imdusiran (AB-729), targets HBV proteins to reduce viral antigens and reawaken the host's immune response. Imdusiran is currently undergoing multiple Phase 2a clinical trials, demonstrating promising results in reducing hepatitis B surface antigen (HBsAg) levels and achieving functional cures in a subset of patients.

Arbutus leverages its proprietary lipid nanoparticle (LNP) technology and expertise in RNAi therapeutics to develop innovative treatments. Beyond HBV, the company has a robust pipeline that includes AB-101, an oral PD-L1 inhibitor, currently in Phase 1a/1b trials. This compound aims to enable controlled checkpoint blockade while minimizing systemic safety issues.

Recent clinical data highlight the potential of Arbutus' combination therapies. In the IM-PROVE I trial, imdusiran combined with pegylated interferon alfa-2a (IFN) and nucleos(t)ide analogue (NA) therapy demonstrated sustained HBsAg loss in some patients, suggesting a path toward a functional cure. Another study, IM-PROVE II, showed that combining imdusiran with VTP-300, an immunotherapeutic, resulted in meaningful reductions in HBsAg levels and the discontinuation of NA therapy in a significant number of patients.

Financially, Arbutus maintains a strong position with a cash runway extending into the first quarter of 2026. They are actively involved in ongoing patent litigation to protect their LNP technology, seeking fair compensation for its use in mRNA COVID-19 vaccines by Moderna and Pfizer/BioNTech.

Arbutus continues to engage in strategic collaborations and partnerships to advance its mission of curing HBV and other chronic infectious diseases. For more detailed information, visit www.arbutusbio.com.

Rhea-AI Summary

Arbutus Biopharma (ABUS) announced promising findings from clinical trials of its RNAi therapeutic, AB-729, showing sustained HBV suppression in patients up to 44 weeks after treatment cessation. Additionally, preclinical data for AB-101, an oral PD-L1 inhibitor, indicate improved HBV immune response when combined with RNAi therapy. However, the company has halted AB-836 development due to safety concerns. Upcoming poster presentations at the AASLD – The Liver Meeting will detail these findings. A conference call is scheduled for November 4, 2022, to discuss these results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
-
Rhea-AI Summary

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that it will present three posters with clinical data at the AASLD Liver Meeting 2022 from November 4-8 in Washington, DC. The presentations will cover findings from its lead compound AB-729 and the preclinical PD-L1 inhibitor AB-101. Key data highlights include:

  • Long-term HBV control in patients after stopping nucleos(t)ide analogue therapy.
  • Increased immune responses in HBV-infected mice with combined treatment.
  • Interim analysis of a Phase 2 study showing safety in various treatment combinations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.42%
Tags
-
Rhea-AI Summary

Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its schedule for the third quarter 2022 financial results and corporate update, set for November 9, 2022. The press release will be available at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET.

The company focuses on developing therapeutics for viral diseases, including HBV and SARS-CoV-2. Notably, its lead compound AB-729 is undergoing evaluation in multiple phase 2 clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.69%
Tags
conferences earnings
Rhea-AI Summary

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that Chief Development Officer Gaston Picchio will depart for personal reasons effective December 31, 2022. The company has begun the search for his successor. CEO William Collier expressed gratitude for Dr. Picchio's contributions, particularly in advancing the clinical pipeline targeting chronic hepatitis B virus (HBV). Arbutus focuses on developing therapeutics aimed at HBV and other viral diseases, including its lead RNAi therapeutic, AB-729, currently in multiple Phase 2 clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
none
-
Rhea-AI Summary

Arbutus Biopharma Corporation (Nasdaq: ABUS) will participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference on October 4, 2022, at 2:30 pm ET. Key executives, including President & CEO William Collier and Chief Scientific Officer Dr. Michael Sofia, will present. A live webcast is available on the company’s website, and an archived replay will follow. Arbutus focuses on discovering therapeutics for viral diseases, particularly Hepatitis B and SARS-CoV-2, with ongoing phase 2 trials for its lead compound AB-729.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.97%
Tags
conferences
-
Rhea-AI Summary

WARMINSTER, Pa., Sept. 06, 2022 – Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in two upcoming investor conferences in New York. They will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13 at 12:30 PM ET, with CEO William Collier as the presenter. Additionally, they will hold a fireside chat at Baird's 2022 Global Healthcare Conference on September 14 at 10:15 AM ET. Live webcasts will be available on their website, with replays accessible post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.52%
Tags
conferences
Rhea-AI Summary

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the issuance of U.S. Patent No. 11,427,823 by the USPTO, granting composition of matter protection for its AB-729 RNAi therapeutic. This patent extends exclusivity for AB-729 until at least April 2038. The company is advancing AB-729 through multiple Phase 2a clinical trials, showing promising safety and efficacy, with significant reductions in hepatitis B surface antigen and DNA levels. Arbutus aims to address the unmet medical needs of over 290 million chronic hepatitis B virus patients globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
-
Rhea-AI Summary

Arbutus Biopharma Corporation (Nasdaq: ABUS) reported their second quarter 2022 financial results, showing a strong financial position with cash and equivalents of $200.6 million, ensuring a runway into Q2 2024. Revenue surged to $14.2 million, up from $2.3 million a year earlier, primarily due to a license agreement with Qilu Pharmaceutical. Clinical advancements were made in their hepatitis B and pan-coronavirus programs, including promising data from their lead therapies AB-729 and AB-836. The company remains focused on its pipeline and upcoming trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
-
Rhea-AI Summary

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its second quarter 2022 financial results and corporate update on August 4, 2022. The company will release its Q2/2022 press release at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. Investors can access the live webcast through the Investors section of Arbutus' website. The company focuses on innovative therapeutics for viral diseases, including Hepatitis B and coronaviruses, and is advancing its lead compound, AB-729, in multiple phase 2 clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
conferences earnings
Rhea-AI Summary

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the continuation of its Phase 2a clinical trial evaluating AB-729, an RNAi therapeutic, in combination with Assembly Biosciences' discontinued vebicorvir and nucleos(t)ide analogue for chronic HBV infection. Despite Assembly's decision to halt VBR development, Arbutus intends to continue patient dosing, with preliminary data expected in the second half of 2022. AB-729 is positioned as a cornerstone in potential HBV treatments, aiming for significant reductions in viral biomarkers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags

FAQ

What is the current stock price of Arbutus Biopharma Corporation (ABUS)?

The current stock price of Arbutus Biopharma Corporation (ABUS) is $3.21 as of December 20, 2024.

What is the market cap of Arbutus Biopharma Corporation (ABUS)?

The market cap of Arbutus Biopharma Corporation (ABUS) is approximately 610.2M.

What is Arbutus Biopharma's primary focus?

Arbutus Biopharma focuses on discovering, developing, and commercializing therapeutics to cure patients suffering from chronic hepatitis B virus (cHBV) infection.

What is imdusiran (AB-729)?

Imdusiran (AB-729) is an RNA interference (RNAi) therapeutic designed to target and reduce HBV proteins, aiding in the reduction of hepatitis B surface antigen and enabling the host's immune system to respond to the virus.

What are the key recent achievements of Arbutus Biopharma?

Recent achievements include promising clinical trial results for imdusiran, showing sustained HBsAg loss and potential functional cure in some patients, as well as ongoing patent litigation to protect their LNP technology used in mRNA COVID-19 vaccines.

What is the status of Arbutus' financial condition?

Arbutus maintains a strong financial position with cash, cash equivalents, and investments providing a cash runway into the first quarter of 2026.

What technologies does Arbutus leverage for its treatments?

Arbutus leverages RNA interference (RNAi) therapeutics and lipid nanoparticle (LNP) technology in developing innovative treatments for HBV and other diseases.

What are the current projects Arbutus Biopharma is working on?

Arbutus is conducting multiple Phase 2a clinical trials for imdusiran in combination with other therapeutics and is evaluating AB-101, an oral PD-L1 inhibitor, in a Phase 1a/1b trial.

Has Arbutus formed any strategic partnerships?

Yes, Arbutus has formed strategic collaborations and partnerships to advance its therapeutic goals and continues to explore new opportunities to enhance its pipeline and clinical programs.

What is the significance of Arbutus' patent litigation?

Arbutus is involved in ongoing lawsuits against Moderna and Pfizer/BioNTech to seek fair compensation for the use of its patented LNP technology in COVID-19 vaccines.

How successful have Arbutus' clinical trials been?

Arbutus' clinical trials have shown promising results, with imdusiran demonstrating significant reductions in HBsAg levels and potential functional cures in some chronic hepatitis B patients.

Where can more information about Arbutus Biopharma be found?

More information about Arbutus Biopharma can be found on their official website at www.arbutusbio.com.

Arbutus Biopharma Corporation

Nasdaq:ABUS

ABUS Rankings

ABUS Stock Data

610.16M
147.20M
22.22%
53.86%
3.2%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WARMINSTER